Semaglutide vs Tirzepatide for Weight Loss: What the Research Actually Says

Key takeaways:

• Tirzepatide consistently produces greater weight loss than semaglutide in head-to-head trials
• Both are FDA-approved for weight management (Wegovy/Zepbound)
• Side effects are similar — GI issues are the most common for both
• Cost is comparable, but insurance coverage varies significantly
• The "better" option depends on your response, tolerance, and access

This is not medical advice. The information below is for educational purposes only. Always consult a qualified healthcare provider before starting any medication. See our full medical disclaimer.

The head-to-head data

The SURMOUNT-5 trial is the first large-scale, head-to-head comparison of tirzepatide vs semaglutide for weight loss. Published in 2024, it enrolled 751 adults with obesity.

Results at 72 weeks:

Metric	Tirzepatide (15mg)	Semaglutide (2.4mg)
Average weight loss	20.2%	13.7%
Patients losing 10%+	81.5%	66.1%
Patients losing 20%+	55.0%	24.5%
Discontinuation (side effects)	4.3%	2.9%

Source: SURMOUNT-5 (NEJM, 2024)

The numbers favor tirzepatide. But averages hide individual variation. Some people respond better to semaglutide. Some cannot tolerate tirzepatide's side effects. The trial tells you what happens on average — not what will happen to you.

How they work

Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your body naturally produces after eating. This slows gastric emptying, reduces appetite, and improves insulin sensitivity.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both GLP-1 and GIP receptors. The dual mechanism appears to produce stronger appetite suppression and greater metabolic effects than GLP-1 alone.

Think of it this way: semaglutide pushes one button. Tirzepatide pushes two.

Side effects comparison

Both medications share similar side effect profiles. GI symptoms are the most common — nausea, vomiting, diarrhea, and constipation.

Side Effect	Semaglutide	Tirzepatide
Nausea	44%	31%
Diarrhea	30%	23%
Vomiting	24%	13%
Constipation	24%	12%

Source: STEP 1 (NEJM, 2021) and SURMOUNT-1 (NEJM, 2022)

Interestingly, tirzepatide shows lower GI side effect rates despite greater weight loss. The dose titration schedule matters — both medications start low and increase gradually to reduce GI symptoms.

Rare but serious risks for both include pancreatitis, gallbladder disease, and potential thyroid concerns (boxed warning for medullary thyroid carcinoma based on animal studies). These risks should be discussed with your doctor.

Cost and access

As of early 2026, both brand-name medications cost roughly $1,000-1,300/month without insurance.

Factor	Semaglutide (Wegovy)	Tirzepatide (Zepbound)
List price	~$1,300/month	~$1,060/month
Insurance coverage	More established	Growing
Compounding available	Limited (patent disputes)	Limited
Generic timeline	2031+	2033+

Insurance coverage is the real differentiator. Some plans cover one but not the other. Check with your provider before assuming either is available at a reasonable cost.

Who is each one better for?

There is no universal answer. But the research patterns suggest:

Tirzepatide may be better if:

• You need maximum weight loss (BMI 35+)
• You have type 2 diabetes (strong dual-pathway metabolic benefits)
• You tolerate GI side effects reasonably well
• Your insurance covers Zepbound

Semaglutide may be better if:

• You want the most studied GLP-1 (longer track record)
• GI side effects are a major concern (some patients tolerate it better)
• Your insurance covers Wegovy but not Zepbound
• You are already responding well to it

My experience

In my experience — and this is purely anecdotal — I started on semaglutide and later switched to tirzepatide. The appetite suppression on tirzepatide felt noticeably stronger. But I also experienced more nausea during the titration period.

Everyone responds differently. What worked for me may not work for you. This is why working with a doctor who can monitor your response matters.

FAQ

Is tirzepatide stronger than semaglutide?

Tirzepatide produces greater average weight loss than semaglutide based on the SURMOUNT-5 head-to-head trial. At the highest doses, tirzepatide achieved 20.2% weight loss compared to semaglutide's 13.7% over 72 weeks. However, individual responses vary significantly.

Can you switch from semaglutide to tirzepatide?

Yes, switching between GLP-1 medications is common under medical supervision. Your doctor will typically have you stop one and start the other at a low dose, titrating up as tolerated. There is usually no washout period required.

Which has fewer side effects — Ozempic or Mounjaro?

Clinical trial data suggests tirzepatide (Mounjaro/Zepbound) has lower rates of nausea, vomiting, and diarrhea than semaglutide (Ozempic/Wegovy), though both cause GI side effects. Individual tolerance varies — some people tolerate one much better than the other.

Are semaglutide and tirzepatide safe long-term?

Both medications have been studied in trials lasting 1-2 years with acceptable safety profiles for their FDA-approved indications. Longer-term data is still being collected. Both carry boxed warnings for thyroid C-cell tumors based on animal studies, though this has not been confirmed in humans.

Bottom line

Tirzepatide produces more weight loss on average. Semaglutide has a longer track record. Both are FDA-approved, supported by strong clinical evidence, and come with similar side effect profiles.

The best choice depends on your specific health profile, insurance coverage, and how your body responds. Work with your doctor to make the call.

---

This article is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. See our full medical disclaimer.

Sources

1. SURMOUNT-5 Trial — Tirzepatide vs Semaglutide head-to-head (NEJM, 2024)
2. STEP 1 Trial — Semaglutide 2.4mg for weight management (NEJM, 2021; PMID: 33567185)
3. SURMOUNT-1 Trial — Tirzepatide for weight management (NEJM, 2022; PMID: 35658024)